Alpha-9 Oncology
Matthias Jaffé is the Chief Financial Officer at Alpha-9 Theranostics Inc. Matthias has extensive experience in the biopharmaceutical industry, previously holding CFO positions at LogicBio Therapeutics, Constellation Pharmaceuticals, Zafgen, Pervasis Therapeutics, MTPV Corporation, and Alantos Pharmaceuticals. Matthias also worked as a Principal at Earlybird Venture Capital and as a Consultant at The Boston Consulting Group. Matthias holds a MBA in Accounting and Finance from INSEAD, a MS in Biology from Massachusetts Institute of Technology, and a BS in Chemistry from Universidad Simón Bolívar.
This person is not in any offices
Alpha-9 Oncology
Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.